These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17407795)

  • 1. Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients.
    Tay EL; Geok-Mui MK; Poh-Hoon MC; Yip J
    Int J Cardiol; 2008 Apr; 125(3):416-7. PubMed ID: 17407795
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of canine pulmonary arterial hypertension: is tadalafil an appropriate alternative to sildenafil?
    Wung D
    Int J Pharm Compd; 2013; 17(1):24-7. PubMed ID: 23627243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension].
    Sakuma M; Shirato K
    Nihon Rinsho; 2008 Nov; 66(11):2157-61. PubMed ID: 19051736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tadalafil for the treatment of pulmonary arterial hypertension.
    Rosenzweig EB
    Expert Opin Pharmacother; 2010 Jan; 11(1):127-32. PubMed ID: 20001434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase inhibitors for pulmonary hypertension.
    Galiè N; Rubin LJ; Simonneau G
    N Engl J Med; 2010 Feb; 362(6):559-60; author reply 560. PubMed ID: 20175298
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
    Ghofrani HA; Grimminger F
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase type 5 inhibitors in pulmonary hypertension: a Hobson's choice for Indian patients.
    Saxena A
    Indian Heart J; 2007; 59(4):299-301. PubMed ID: 19126933
    [No Abstract]   [Full Text] [Related]  

  • 9. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors.
    Dresser MJ; Desai D; Gidwani S; Seftel AD; Modi NB
    Int J Impot Res; 2006; 18(1):104-10. PubMed ID: 16307008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.
    Chaumais MC; Perrin S; Sitbon O; Simonneau G; Humbert M; Montani D
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1193-205. PubMed ID: 23944387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects.
    Lim ZS; Salmon AP; Vettukattil JJ; Veldtman GR
    Int J Cardiol; 2007 May; 118(2):178-82. PubMed ID: 17027100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil.
    Ahn TY; Lee SW; Kim SW; Yang DY; Park NC; Min KS; Park K; Paick JS; Dyachkova Y; Dwight T; Lee MS
    Asian J Androl; 2007 Nov; 9(6):760-70. PubMed ID: 17968461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension.
    Wong RC; Koh GM; Choong PH; Yip WL
    Int J Cardiol; 2007 Jul; 119(3):400-2. PubMed ID: 17064789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension.
    Affuso F; Palmieri EA; Di Conza P; Guardasole V; Fazio S
    Int J Cardiol; 2006 Apr; 108(3):429-31. PubMed ID: 16260051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use?
    Chapman TH; Wilde M; Sheth A; Madden BP
    Vascul Pharmacol; 2009; 51(2-3):90-5. PubMed ID: 19386283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of sildenafil in children with pulmonary arterial hypertension].
    He CY
    Zhongguo Dang Dai Er Ke Za Zhi; 2010 Jun; 12(6):509-12. PubMed ID: 20540870
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
    Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
    Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in researches on the onset and duration of the action of sildenafil].
    Wang HP; Pu XY
    Zhonghua Nan Ke Xue; 2005 May; 11(5):392-5. PubMed ID: 15934467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sildenafil improves survival in idiopathic pulmonary arterial hypertension.
    Sastry BK; Raju BS; Narasimhan C; Prakash GS; Reddy NK; Ananad B
    Indian Heart J; 2007; 59(4):336-41. PubMed ID: 19126939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.